With many available clinical, radiologic, and pathologic patterns and combinations thereof,
diagnosis of interstitial lung disease (ILD) subtypes has been colloquially described as an …

Many therapies have been investigated for systemic sclerosis-associated interstitial lung
disease (SSc-ILD), including immunosuppressive therapies, antifibrotic agents …

Interstitial lung disease (ILD) is commonly present in patients with an underlying connective
tissue disease (CTD), particularly those with systemic sclerosis, rheumatoid arthritis, and …

A significant proportion of patients with interstitial lung disease (ILD) may develop a
progressive fibrosing phenotype characterized by worsening of symptoms and pulmonary …

Interstitial lung disease is a common pulmonary manifestation of connective tissue diseases
and results in significant morbidity and mortality. Although all connective tissue diseases are …

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1%
of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary …

ABSTRACT Introduction: Systemic sclerosis (SSc) is a rare and complex connective tissue
disease characterized by fibrosis of the skin and internal organs. Interstitial lung disease …

Interstitial lung disease (ILD) is a cause of morbidity and mortality in patients with rheumatic
diseases, such as connective-tissue diseases, rheumatoid arthritis and systemic vasculitis …

Interstitial lung disease (ILD) affects the majority of patients with systemic sclerosis (SSc)
and is the leading cause of death in SSc. Traditionally, treatments for SSc-ILD have targeted …

The connective tissue diseases (CTDs) are a group of inflammatory, immune-mediated
disorders in which a failure of self-tolerance leads to autoimmunity and subsequent tissue …